Hikma v. Amarin: Supreme Court Examines Induced Infringement in the Context of Generic Drug Labeling
by Nafsika Karavida and Lucia Mead Last month, the Supreme Court of the United States heard oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., a landmark pharmaceutical patent dispute concerning whether a generic drug manufacturer may face liability for induced patent infringement after marketing a “skinny-label” generic...